|
Oct 14
|
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 1
|
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
|
|
Sep 28
|
Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations
|
|
Sep 27
|
Q4 2024 Aytu Biopharma Inc Earnings Call
|
|
Sep 26
|
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
|
|
Jun 18
|
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
|
|
May 15
|
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
|
|
May 8
|
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
|
|
Apr 3
|
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
|
|
Apr 3
|
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
|
|
Jan 23
|
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
|
|
Jan 16
|
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?
|
|
Dec 6
|
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now
|
|
Nov 30
|
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
|
|
Aug 9
|
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-Term
|
|
Aug 8
|
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
|
|
May 1
|
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
|
|
Apr 27
|
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
|